Unregistered User If this is not your name, click here.
		Contact Us | Order Now | Journals | Bookstore | Register a colleague
	Select a ChannelAcneAIDS and HIVAllergy OtherAlzheimer'sAnaesthesiology OtherAngina Pectoris/MIAnxietyArthritis OtherAsthmaBack PainBacterial InfectionsBladder CancerBone Marrow TransplantationBreast CancerCardiology OtherCataractCell TransplantationCervical CancerCholesterol/Lipid disordersCirrhosisClinical PharmacologyColorectal CancerCongestive Heart FailureContact DermatitisContraceptionCOPDCystic FibrosisDental and Oral DisordersDepressionDermatology OtherDiabetesDialysisEating DisordersElbowEmergency MedicineEndocrinology OtherEpilepsyErectile DysfunctionFibromyalgiaGastro OtherGeneticsGenitourinary OtherGeriatricsGERD/GastritisGlaucomaH. Pylori/UlcerHaematology OtherHair LossHeadachesHepa/Biliary OtherHepatitisHipHRTHypertensionIBDImmunologyInfectious OtherInfertilityIntensive CareIrritable Bowel SyndromeKneeLeukemiasLiver CancerLung CancerLupusLymphomasMelanomaMenopauseMultiple Sclerosis Nephrology OtherNeurologic OtherNutritional / Metabolic OtherOb/Gyn OtherObesityOncology OtherOphth. OtherOphthalmic SurgeryOrgan TransplantationOrthopaedics OtherOsteoarthritisOsteoporosisOtitisOtorhino. OtherOvarian CancerPaediatricsPainPancreatic CancerParkinson'sPregnancyProstate CancerPsychiatry OtherPulmonary OtherRadiologyRenal CancerRenal FailureRespiratory InfectionsRheumatoid arthritisRheumatology OtherRhinitisSchizophreniaShoulderSleep ApnoeaSleep DisordersSpineStrokeSTDsSurgeryThyroid DisordersTransfusionTransplant Surgery OtherTraumaUrinary IncontinenceUrinary tract infectionsVaccinologyVascular DisordersViral Infections

SEARCH   News Bookstore Medline The Web Meetings & Congresses Complete Doctor's Guide    EXPLORE :    All News   All Webcasts   All Cases   All Meetings & Congresses   All Medical Resources New drugs / indications English Dictionary Medical Dictionary Thesaurus Warning | Privacy | Awards  Favourite Journals  Click here to choose your favourite journals  Favourite Sites  Click here to choose your favourite sites  Languages  Select languageEnglishFrançais

Myotrophin Cleared by FDA Early Access Program for Patients with ALS WEST CHESTER, Pa., and EMERYVILLE, Calif., June 24, 1996 -- Cephalon, Inc. (Nasdaq: CEPH) and its partner, Chiron Corporation (Nasdaq: CHIR), announced today that the U.S. Food and Drug Administration (FDA) has cleared a Treatment Investigational New Drug (T-IND) early access program for the use of Myotrophin(R) (rhIGF-1) in patients with amyotrophic lateral sclerosis (ALS) in the United States. Patient registration and other information about the Myotrophin early access program will be announced separately once program details are completed and finalized with the FDA. Cephalon and Chiron are developing Myotrophin in North America and Europe for the treatment of ALS and other neuromuscular conditions. Chiron Corporation is a science-driven healthcare company that combines diagnostic, vaccine and therapeutic strategies for controlling disease. Headquartered in Emeryville, Calif., with operations on four continents, Chiron had revenues in 1995 of $1.1 billion. Cephalon discovers, develops and markets pharmaceutical products for the treatment of neurological diseases and disorders. The company's principal focus is on diseases and disorders such as ALS, narcolepsy, peripheral neuropathies, Alzheimer's disease, head and spinal injury, and stroke. E-mail this page to a friend or colleague! To print, use this version